Interleukin-15 and Its Soluble Receptor Mediate the Response to Infliximab in Patients With Crohn's Disease

Gastroenterology

Volumn 138, Issue 7, 2010, Pages 2378-2387

  Bouchaud, Gregory ^a,b   Mortier, Erwan ^a,b   Flamant, Mathurin ^a,c   Barbieux, Isabelle ^a,b   Plet, Ariane ^a,b   Galmiche, Jean Paul ^a,c   Jacques, Yannick ^a,b   Bourreille, Arnaud ^a,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔTEL DIEU   (France)

Author keywords

Crohn's Disease; Epithelial Cell; Infliximab; Interleukin 15 Receptor Alpha Subunit

Indexed keywords

A DISINTEGRIN; ADALIMUMAB; CORTICOSTEROID; DISINTEGRIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; MATRIX METALLOPROTEINASE 17; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HT29; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION;

EID: 77952832453     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.02.044     Document Type: Article

References (28)

1. Eissner G., Kolch W., and Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 15 (2004) 353-366
2. Friedmann E., Hauben E., Maylandt K., et al. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 8 (2006) 843-848
3. Kirchner S., Holler E., Haffner S., et al. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28 (2004) 67-74
4. Mitoma H., Horiuchi T., Hatta N., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128 (2005) 376-392
5. Nesbitt A., Fossati G., Bergin M., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13 (2007) 1323-1332
6. Bulfone-Pau S.S., Bulanova E., Pohl T., et al. Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J 13 (1999) 1575-1585
7. Bulfone-Paus S., Ungureanu D., Pohl T., et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 3 (1997) 1124-1128
8. Mortier E., Bernard J., Plet A., et al. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 173 (2004) 1681-1688
9. Budagian V., Bulanova E., Orinska Z., et al. Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem 279 (2004) 40368-40375
10. Mortier E., Woo T., Advincula R., et al. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205 (2008) 1213-1225
11. Bouchaud G., Garrigue-Antar L., Solé V., et al. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol 382 (2008) 1-12
12. Mortier E., Quéméner A., Vusio P., et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of Il-15 action through Il-15R beta/gamma. Herperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 281 (2006) 1612-1619
13. Kirman I., and Nielsen O.H. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis. Am J Gastroenterol 91 (1996) 1789-1794
14. Sakai T., Kusugami K., Nishimura H., et al. Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease. Gastroenterology 114 (1998) 1237-1243
15. Nishiwaki T., Ina K., Goto H., et al. Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease. J Gastroenterol 40 (2005) 128-136
16. Yoshihara K., Yajima T., Kubo C., et al. Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice. Gut 55 (2006) 334-416
17. Obermeier F., Hausmann M., Kellermeier S., et al. IL-15 protects intestinal epithelial cells. Eur J Immunol 36 (2006) 2697-2699
18. Bernard J., Harb C., Mortier E., et al. Identification of an interleukin-15alpha receptor-binding site on human interleukin-15. J Biol Chem 279 (2004) 24313-24322
19. Badoual C., Bouchaud G., Agueznay Nel H., et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 68 (2008) 3907-3914
20. Duitman E.H., Orinska Z., Bulanova E., et al. How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha. Mol Cell Biol 28 (2008) 4851-4861
21. Dideberg V., Theatre E., Farnir F., et al. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics 16 (2006) 727-734
22. Kageyama Y., Takahashi M., Torikai, et al. Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 4 (2007) 505-509
23. Yoshihara K., Yamada H., Hori A., et al. IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol 37 (2007) 2744-2752
24. Ruchatz H., Leung B.P., Wei X., et al. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 160 (1998) 5654-5660
25. Boirivant M., Marini M., Di Felice G., et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116 (1999) 557-565
26. Di Sabatino A., Ciccocioppo R., Cinque B., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53 (2004) 70-77
27. Pereno R., Gaggero A., Scudeletti M., et al. IL-15/IL-15R alpha intracellular trafficking in human cells and protection from apoptosis. Ann N Y Acad Sci 876 (1999) 236-245
28. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838